- Home
- MFH vs MBX Comparison
MFH vs MBX Comparison
Compare MFH & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFH
- MBX
- Stock Information
- Founded
- MFH 2011
- MBX 2018
- Country
- MFH United States
- MBX United States
- Employees
- MFH N/A
- MBX N/A
- Industry
- MFH Finance: Consumer Services
- MBX
- Sector
- MFH Finance
- MBX
- Exchange
- MFH Nasdaq
- MBX NYSE
- Market Cap
- MFH 372.5M
- MBX 300.5M
- IPO Year
- MFH N/A
- MBX 2024
- Fundamental
- Price
- MFH $6.08
- MBX $11.11
- Analyst Decision
- MFH
- MBX Strong Buy
- Analyst Count
- MFH 0
- MBX 5
- Target Price
- MFH N/A
- MBX $37.40
- AVG Volume (30 Days)
- MFH 92.0K
- MBX 333.6K
- Earning Date
- MFH 05-16-2025
- MBX 05-16-2025
- Dividend Yield
- MFH N/A
- MBX N/A
- EPS Growth
- MFH N/A
- MBX N/A
- EPS
- MFH N/A
- MBX N/A
- Revenue
- MFH $1,007,430.00
- MBX N/A
- Revenue This Year
- MFH N/A
- MBX N/A
- Revenue Next Year
- MFH N/A
- MBX N/A
- P/E Ratio
- MFH N/A
- MBX N/A
- Revenue Growth
- MFH 125.92
- MBX N/A
- 52 Week Low
- MFH $1.03
- MBX $4.81
- 52 Week High
- MFH $8.86
- MBX $27.50
- Technical
- Relative Strength Index (RSI)
- MFH 47.24
- MBX N/A
- Support Level
- MFH $5.30
- MBX N/A
- Resistance Level
- MFH $7.90
- MBX N/A
- Average True Range (ATR)
- MFH 0.81
- MBX 0.00
- MACD
- MFH -0.08
- MBX 0.00
- Stochastic Oscillator
- MFH 30.00
- MBX 0.00
About MFH Mercurity Fintech Holding Inc.
Mercurity Fintech Holding Inc is a New York-based digital fintech leader providing access to the rapidly growing AI-powered infrastructure, blockchain, and digital assets sectors. Its three core business lines include: 1. Blockchain and digital asset solutions. 2. AI and HPC infrastructure, specializing in developing liquid cooling solutions for AI data centers. 3. Comprehensive financial services.
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.